Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626182 · ClinicalTrials.gov registry record · Phase 1
Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF
A Phase 1 study, sponsored by National Jewish Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02626182 is a Phase 1 study that has completed, run by National Jewish Health. The registered enrollment target is 14 participants.
The verdict
NCT02626182, a Phase 1 study, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study evaluates the ability of the drug sildenafil to improved exercise capacity, cardiac performance during exercise, and quality of life in patients with moderate to severe CF lung disease. 3/4 of the subjects will receive sildenafil and 1/4 will receive placebo.
Interventions
- DRUG placebo
- DRUG sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-01-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02626182
The ClinicalTrials.gov registry entry for NCT02626182 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02626182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02626182 about?
NCT02626182 is a clinical study titled "Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF". This study evaluates the ability of the drug sildenafil to improved exercise capacity, cardiac performance during exercise, and quality of life in patients with moderate to severe CF lung disease. 3/4 of the subjects will receive sildenafil and 1/4 will receive placebo.
What is the current status of trial NCT02626182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2015-12. Estimated completion is 2018-01-29.
What interventions are being tested in trial NCT02626182?
The interventions under investigation include: placebo (DRUG), sildenafil (DRUG).
Who is sponsoring clinical trial NCT02626182?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.